REG - 3i Infrastructure - 3i Infrastructure plc agrees to acquire Ionisos

3i InfrastructureAnnouncement

26/07/2019 07:05

RNS Number : 7909G
3i Infrastructure PLC
26 July 2019
 


 
3i Infrastructure plc agrees to acquire Ionisos
26 JULY 2019
 
3i Infrastructure plc ("3i Infrastructure") has agreed to invest c. €220m to acquire up to 100% of Ionisos, a leading owner and operator of cold sterilisation facilities servicing the medical, pharmaceutical and cosmetics industries, from Ardian Expansion. Completion is expected to take place in September.
 
Established in 1993 in Civrieux, France, Ionisos is the third largest cold sterilisation provider globally and operates a network of 11 facilities in Europe with market leading positions in France and Spain. It has over 200 employees and a highly diversified customer base of more than 1,000 customers. Ionisos delivers a mission-critical service for the medical, pharmaceutical and cosmetics industries for whom cold sterilisation is an essential component of the manufacturing process. It is typically applied to single use products that would be damaged by the heat and/or humidity of hot sterilisation methods.
 
Demand for sterilisation is driven by attractive market fundamentals and non-cyclical market factors, including an ageing population in Western Europe, growing demand for medical services increasingly relying on single use products, and increasingly stringent regulation governing the sterilisation of medical, pharmaceutical and cosmetics products.
 
Richard Laing, Chair of 3i Infrastructure, commented: "Ionisos represents a great opportunity for 3i Infrastructure to diversify its sector exposure and increase its presence in the French market. It is a resilient business providing essential infrastructure to sectors with attractive long-term fundamentals."
 
Phil White, Managing Partner and Head of Infrastructure, 3i Investments plc, Investment Manager of 3i Infrastructure, added: "Ionisos is a defensive business which has grown organically and through bolt-on M&A.  We look forward to working with the management team to continue its strong track record of providing market-leading services while growing its presence across Europe."
 
Christoph Herkens, CEO of Ionisos said: "3i Infrastructure has a strong international team and network which we feel will be of great support as we accelerate our growth through acquisition, organic growth and further development of our business across Europe. Its permanent capital and long-term perspective make it an attractive partner."
 
-ENDS-
For further information, contact:
 



 
Thomas Fodor
Investor enquiries
 
Kathryn van der Kroft
Media enquiries
 


 
Tel: +44 207 975 3469
Email: thomas.fodor@3i.com
 
Tel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com
 



 
 
Notes to editors:
 
3i Infrastructure plc
 
3i Infrastructure plc is a Jersey-incorporated, closed-ended investment company, an approved UK Investment Trust (with effect from 15 October 2018), listed on the London Stock Exchange and regulated by the Jersey Financial Services Commission.  It is a long-term investor in infrastructure businesses and assets.  Its market focus is on economic infrastructure and greenfield projects in developed economies, principally in Europe, investing in operating businesses and projects which generate long-term yield and capital growth.
 
3i Investments plc, a wholly-owned subsidiary of 3i Group plc, is authorised and regulated in the UK by the Financial Conduct Authority and is the investment manager of 3i Infrastructure plc.
 
About Ionisos
 
Ionisos is a French company founded in 1993, which manages eleven plants in France, Spain, Germany, Estonia and Italy. Ionisos is a specialist in cold sterilisation using ionisation and ethylene oxide for the medical sector, pharmaceutical products, cosmetics and food packaging.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQFELLLKDFFBBB